Hematology-Oncology
Latest news
316 articles · 20 / page
Ferritin-Guided Iron Supplementation in Blood Donors: Evidence Synthesis and Clinical Implications from the FORTE Trial and Related Studies
Iron supplementation guided by ferritin levels effectively mitigates iron deficiency and anaemia in regular blood donors, offering a practical alternative or adjunct to extending donation intervals.
Advancing Care in Older Adult T-Cell Leukemia/Lymphoma: Phase 2 Trial of Moga-CHOP-14 Combination Therapy
A phase 2 study demonstrated that combining mogamulizumab with CHOP chemotherapy improves progression-free survival in older patients with adult T-cell leukemia/lymphoma, highlighting a promising first-line option.
Ultrasensitive Circulating Tumor DNA as a Superior Biomarker for Remission Assessment in Large B-cell Lymphoma
Detection of circulating tumor DNA (ctDNA) provides a highly prognostic method for assessing remission in large B-cell lymphoma, outperforming conventional imaging and promising improved patient outcomes.
Oral Realgar-Indigo Naturalis Formula Matches Arsenic Trioxide Efficacy in Non-High-Risk Acute Promyelocytic Leukemia: Insights from a Multicenter Randomized Trial
A pivotal multicenter randomized trial demonstrates that oral Realgar-Indigo naturalis formula (RIF) combined with ATRA is non-inferior to arsenic trioxide (ATO) plus ATRA, providing a simplified consolidation regimen for non-high-risk APL
Sustained Remission in Acute Promyelocytic Leukemia with ATO-ATRA and Gemtuzumab Ozogamicin: Long-Term Phase 2 Outcomes
A phase 2 study shows that combining all-trans retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin yields a 94% cure rate in acute promyelocytic leukemia with favorable safety over five years.
APOLLO Trial Highlights Superior Efficacy of Arsenic Trioxide Plus ATRA in High-Risk Acute Promyelocytic Leukemia
The phase III APOLLO trial demonstrates that arsenic trioxide combined with all-trans retinoic acid (ATRA) plus low-dose idarubicin improves event-free survival and reduces relapse rates compared to standard ATRA plus anthracycline chemothe
Reversing PD-1 Resistance in Advanced Melanoma: Insights from the SPOTLIGHT-203 Phase II Trial of BO-112 Plus Pembrolizumab
The SPOTLIGHT-203 Phase II trial demonstrates that intratumoral BO-112 combined with pembrolizumab shows promise by achieving a 25% ORR in anti-PD-1-resistant advanced melanoma with manageable safety, offering a potential new therapeutic av
Unraveling the Prognostic Impact of Co-Occurring High-Risk Cytogenetic Abnormalities in Multiple Myeloma
A meta-analysis of 24 trials involving 13,926 patients establishes that concurrent high-risk cytogenetic abnormalities markedly worsen progression-free and overall survival in both newly diagnosed and relapsed multiple myeloma, underscoring
Promising Frontline Triplet Therapies for IDH-Mutated AML Patients Ineligible for Intensive Chemotherapy
Triplet regimens combining hypomethylating agents, venetoclax, and IDH inhibitors demonstrate high remission rates and survival in intensive chemotherapy-ineligible IDH-mutant AML patients, warranting further comparative studies against app
Prolonged Hospitalization Post-Hematopoietic Cell Transplantation: Identifying Risk Factors and Impacts on Patient Outcomes
This study reveals that prolonged hospitalization after hematopoietic cell transplantation correlates with worse quality of life, greater symptom burden, increased depressive symptoms, and higher risk of rehospitalization and mortality with
Multisite Randomized Trial of Inpatient Palliative Care in Hematopoietic Stem Cell Transplantation: Enhancing Patient and Caregiver Outcomes
Inpatient palliative care during hematopoietic stem cell transplantation improves patients’ quality of life, reduces depression and PTSD symptoms, and offers sustained psychological benefits up to six months post-transplant.
Lisocabtagene Maraleucel: Transforming Second-Line Therapy in Relapsed/Refractory Large B-Cell Lymphoma — Insights from the 3-Year TRANSFORM Study Follow-Up
The 3-year follow-up of the phase III TRANSFORM study demonstrates that lisocabtagene maraleucel (liso-cel) provides superior durable efficacy and a favorable safety profile compared with standard of care in second-line relapsed/refractory
Potential Curative Impact of Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma: Five-Year Outcomes from CARTITUDE-1
CARTITUDE-1 demonstrates that a single infusion of ciltacabtagene autoleucel (cilta-cel) yields durable ≥5-year remission and extended survival in heavily pretreated relapsed/refractory multiple myeloma, with compelling MRD negativity and a
Improving Outcomes in Mismatched Unrelated Donor Stem Cell Transplants With Post-Transplant Cyclophosphamide
Post-transplant cyclophosphamide (PTCy) for graft-versus-host disease prophylaxis significantly improves 1-year survival and lowers severe GVHD rates in mismatched unrelated donor peripheral blood stem cell transplants, expanding access for
Innovative All-Oral Therapy: Linperlisib Plus Chidamide Shows Promise in Relapsed or Refractory Cutaneous T-Cell Lymphoma
A phase 1 trial of linperlisib combined with chidamide demonstrated manageable safety and notable efficacy in relapsed/refractory CTCL, offering a potential new oral treatment option for advanced disease, especially mycosis fungoides.
Novel Efficacy and Safety of Obinutuzumab Combined with Lenalidomide in First-Line Treatment of High Tumor Burden Follicular Lymphoma
This phase 2 study demonstrates that obinutuzumab plus lenalidomide achieves high response rates with durable progression-free survival and manageable toxicities in untreated high tumor burden follicular lymphoma, suggesting a promising fro
Optimizing Therapy in Transplant-Ineligible Multiple Myeloma: Insights from the REST Phase 2 Trial on Isatuximab, Bortezomib, Lenalidomide, and Limited Dexamethasone
The REST trial demonstrated that combining isatuximab with weekly bortezomib, lenalidomide, and limited dexamethasone yields promising efficacy and manageable safety in older patients with transplant-ineligible multiple myeloma.
ENHANCE-3 Trial: Evaluating Magrolimab Addition to Venetoclax and Azacitidine in Untreated AML Unfit for Intensive Chemotherapy
The ENHANCE-3 phase 3 trial assessed whether adding magrolimab to venetoclax and azacitidine improves outcomes in untreated AML patients unfit for intensive chemotherapy, finding no survival benefit and a higher rate of fatal adverse events
Five-Year Outcomes of FCARH143: A Fully Human BCMA CAR-T Therapy in Relapsed/Refractory Multiple Myeloma
FCARH143, a fully human BCMA-directed CAR-T cell therapy, shows remarkable long-term efficacy and manageable safety profile in heavily pretreated relapsed/refractory multiple myeloma patients over 5 years.
Clonal Hematopoiesis and Its Link to Severe Cytokine Release Syndrome in CAR T-Cell Therapy Recipients
Clonal hematopoiesis (CH) occurs frequently in patients receiving CD19 or BCMA CAR T therapy and correlates with a higher risk of severe cytokine release syndrome (CRS), suggesting CH as a potential biomarker for CRS risk and a target for p
Browse by specialty
Open language-specific specialty feeds and department pages.